<DOC>
	<DOCNO>NCT00185393</DOCNO>
	<brief_summary>The aim study test [ 90 ] Y-ibritumomab tiuxetan , radioactive antibody , patient stage III IV follicular lymphoma whose disease partial complete remission first line chemotherapy . The radioactive antibody compare treatment see good long term standard lymphoma treatment .</brief_summary>
	<brief_title>Treatment With 90Y-Ibritumomab Tiuxetan Versus Treatment Patients With Follicular Non Hodgkin Lymphoma ( Stage III IV ) Having Achieved Partial Complete Remission After First Line Chemotherapy</brief_title>
	<detailed_description>The study previously post Schering AG , Germany . Schering AG , Germany rename Bayer Schering Pharma AG , Germany . Bayer Schering Pharma AG , Germany sponsor trial .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Non Hodgkin Lymphoma stage III IV timepoint diagnosis Patients achieve remission first line chemotherapy No le 6 week 12 week since last dose chemotherapy old 18 year write informed consent Any anticancer treatment NHL except precede first line chemotherapy Prior radiation therapy Patients recover toxic effect first line chemotherapy Any cancer history cancer le 10 year ago Patients know HIV positivity patient pleural effusion ascites female patient pregnant breast feeding ( woman childbearing potential must negative serum pregnancy test study entry ) Adults employ effective method birth control study treatment 12 month thereafter Patients unable unwilling comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Follicular Non Hodgkin lymphoma</keyword>
</DOC>